Bayer v. Watson Laboratories

In this case, Goodwin attorneys persuaded the Federal Circuit to reverse a district court decision and find a patent relating to an orally disintegrating tablet formulation of vardenafil (an erectile dysfunction treatment branded as Staxyn) invalid for obviousness.  The unanimous Federal Circuit decision held that the district court’s purported credibility determination regarding the parties’ experts did not support the judgment, because the court failed to address numerous prior art references demonstrating a motivation to develop an ODT formulation for vardenafil.

Bayer v. Watson Laboratories Appellants Opening Brief

Bayer v. Watson Laboratories Appellants Reply Brief

Download PDF